Effectively suppressing PI3K/AKT signaling by pharmacological agents could be resistant to cardiac hypertrophy when mouse hearts are exposed to chronic pressure overload, as evidenced by that Isorhamnetin (Gao et al., 2017) and Astragaloside IV (Liu et al., 2018) protect against cardiac hypertrophy through inactivation of PI3K/AKT pathway. This evidence concerns the gene AKT1 and cardiac hypertrophy.